BioWorld Asia

July 12, 2006

Intercell's €110M Funding Provides Exit Opportunity

Intercell AG rounded off the largest fund raising in Europe this year, with the placing of an overallotment of 1.3 million shares, bringing the total to €110.6 million (US$140.9 million). (BioWorld International) Read More

Genmab's Humax-CD20 Starts Phase III Work With NHL Focus

Breast Cancer Gene Might Mean Help For More Women

Novozymes Getting Protein Production, More From Delta

Early Funding Source To Be Provided By IP Group

Eurofins Scientific Invests In Danish, Japanese Food Firms

LTKfarma Setting Up Shop With Product In Phase I/II

Paradigm's Fourth Round: £7M For Cancer Drug Trials

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 26, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...

Illustration of red and white blood cells in an artery

Case report links APOLD1 variant to vascular-type bleeding disorder

BioWorld Science

Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.

2026 marks critical turning point for BCI technology

BioWorld

Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...